Quest Diagnostics Inc (DGX.N)
58.74USD
12:55pm EDT
$0.04 (+0.07%)
$58.70
$58.52
$58.85
$58.40
94,429
319,164
$64.85
$55.16
About
Overall
| Beta: | 0.61 |
| Market Cap (Mil.): | $8,915.72 |
| Shares Outstanding (Mil.): | 151.89 |
| Dividend: | 0.30 |
| Yield (%): | 2.04 |
Financials
| DGX.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 17.59 | 23.62 | 37.87 |
| EPS (TTM): | 3.34 | -- | -- |
| ROI: | 7.20 | 7.46 | 18.70 |
| ROE: | 13.40 | 11.89 | 19.53 |
Quest Diagnostics reports third profit miss in a row
- Laboratory tests provider Quest Diagnostics Inc's results missed analysts' expectations for the third straight quarter, hurt by a cut in Medicare reimbursements.
Quest Diagnostics profit misses estimates
July 18 - Laboratory tests provider Quest Diagnostics Inc's results missed analysts' expectations for the third straight quarter, hurt by a cut in Medicare reimbursements.
Quest profit misses estimates, deals to drive growth
- Laboratory tests provider Quest Diagnostics Inc, whose earnings have been hurt by Medicare reimbursement cuts, said growth this year will be driven by acquisitions.
Quest profit misses estimates, deals to drive growth
- Laboratory tests provider Quest Diagnostics Inc, whose earnings have been hurt by Medicare reimbursement cuts, said growth this year will be driven by acquisitions.
UPDATE 2-Quest profit misses estimates, deals to drive growth
April 17 - Laboratory tests provider Quest Diagnostics Inc, whose earnings have been hurt by Medicare reimbursement cuts, said growth this year will be driven by acquisitions.
Quest first quarter profit misses estimates
- Laboratory tests provider Quest Diagnostics Inc's quarterly profit missed analysts estimates as Medicare reimbursement cuts ate into its margins, sending its shares down 4 percent before the bell.
Quest 1st-qtr profit misses estimates
April 17 - Laboratory tests provider Quest Diagnostics Inc's first-quarter profit missed Wall Street's average estimate as Medicare reimbursement cuts ate into its revenue.
UPDATE 2-Quest CFO to leave as company restructures
March 14 - Laboratory tests provider Quest Diagnostics on Thursday said its Chief Financial Officer Robert Hagemann will leave at the end of May as the company continues a restructuring aimed at returning to revenue growth.
Quest CFO to step down at the end of May
March 14 - Laboratory tests provider Quest Diagnostics said Chief Financial Officer Robert Hagemann will leave the company at the end of May.
TEXT-Fitch affirms Quest Diagnostics IDR, outlook revised to stable
Feb 22 - Fitch Ratings has affirmed Quest Diagnostics, Inc.'s (Quest) Issuer Default Rating (IDR) at 'BBB+'. A complete list of ratings is provided at the end of this release. The ratings apply to approximately $3.36 billion of outstanding debt. The Rating Outlook is revised to Stable from Negative. KEY RATING DRIVERS Debt Leverage Within Goal Quest has reduced leverage (total debt to EBITDA) during 2012 into its stated target range of 2.0 times (x) to 2.25x, a level Fitch considers to be c
Competitors
| Price | Change | |
|---|---|---|
| Laboratory Corp. of America Holdings (LH.N) | $97.54 | +0.15 |
| Bio-Reference Laboratories Inc (BRLI.OQ) | $25.96 | -0.41 |
| Sonic Healthcare Limited (SHL.AX) | $14.55 | +0.10 |
| Ventas, Inc. (VTR.N) | $65.28 | +0.56 |
| Johnson & Johnson (JNJ.N) | $93.89 | +0.12 |
| GlaxoSmithKline plc (GSK.L) | 1,712.50p | 0.00 |
| Pfizer Inc. (PFE.N) | $29.30 | +0.19 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Trading Report for (DGX). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

